FINWIRES · TerminalLIVE
FINWIRES

Tecsys Initiated with Buy Rating, C$39 Price Target at TD

By

TD Securities initiated coverage of Tecsys (TCS.TO) with a Buy rating and C$39 price target on Wednesday.

Tecsys "enjoys a strong reputation and word of mouth within the healthcare supply chain market, and we expect this to benefit its healthy growth profile driven by market share gains and ARPU growth," analyst John Shao said in a note. "We see TCS as a high-quality but still under the radar supply chain software name with a multi-year growth runway ahead."

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Related Articles

Research

BofA Securities Initiates Coverage on SPX Technologies With Buy Rating, $235 Price Target

SpaceX (SPCX) has an average rating of overweight and mean price target of $220.81, according to analysts polled by FactSet.Price: $219.24, Change: $-12.95, Percent Change: -5.58%

$SPXC
Research

Wells Fargo Upgrades MGM Resorts International to Equalweight From Underweight, Price Target is $48.30

MGM Resorts International (MGM) has an average rating of overweight and mean price target of $48.91, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $46.81, Change: $-0.07, Percent Change: -0.15%

$MGM
Research

LifeSci Capital Downgrades Crinetics Pharmaceuticals to Market Perform From Outperform, Price Target is $85

Crinetics Pharmaceuticals Inc (CRNX) has an average rating of overweight and mean price target of $83.18, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$CRNX